Winona
Winona is a women's telehealth platform founded in 2019 with a clinical focus on menopause and perimenopause. It offers hormone replacement therapy (HRT) as its primary service, with GLP-1 weight management added as a significant secondary program. All clinicians on the platform are female, which reflects a deliberate design choice for a demographic that often reports feeling dismissed or under-served in standard clinical settings. Winona serves women generally 40 and older.
Overview
- Consultation Model
- Hybrid
- Headquarters
- United States
- Shipping
- 3-5 business days
- Lab Testing
- No
- Prescriber Info
- Licensed healthcare providers evaluate patients and prescribe based on clinical eligibility.
- Founded
- 2019
Pros
- Female-only clinician panel is a meaningful differentiator for the 40+ demographic
- Integrated HRT + GLP-1 co-management addresses the actual biology of perimenopause-related weight gain
- Detailed hormonal intake creates more clinical context than standard weight-loss telehealth intake forms
- Asynchronous model is accessible and does not require scheduling around rigid appointment slots
- Platform designed specifically for this population
Cons
- Not appropriate for women outside the perimenopausal/menopausal demographic seeking GLP-1 treatment
- Cash-pay model with limited insurance integration means costs are fully out-of-pocket for most patients
- Compounded semaglutide availability is uncertain post-FDA enforcement; patients should confirm formulation options at time of consultation
- Async-first model may be insufficient for patients with complex or rapidly changing metabolic presentations
- Less brand recognition than larger platforms, which may make some patients hesitant despite clinical appropriateness